First TIL Results: Four Patients, All Responded, One Complete; Panel Pens Reauthorization Drive
In Brief: Lepovetsky Heads New NCI Office Of Technology Development; Temporary Now, Maybe Permanent
FDA Advisory Committee To Consider NDAs On Novantrone, HD MTX
ACS Modifies Pap Test Guidelines
Cancer Letter, PR Firm Settle Out Of Court On Copyright Violation
Comments Invited On Centers Program
Radiation Exposure Mostly Natural, NCRP Report Says
Trending Stories
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Johnson and Johnson reaches $5.5B settlement deal over talc lawsuits
- What happened at FDA? Replimune approval raises questions
- I grew up unhoused. Now, with support from ACS, I am an MD-PhD student focused on oncology
My mother instilled in me: “Never become a product of your circumstances.” - Duke Officials Silenced Med Student Who Reported Trouble in Anil Potti’s Lab
- FDA grants Replimune’s RP1 an accelerated approval on third submission after 10:3 vote from advisory committee
Amid political outcry, advisors accept weak data and give sponsor a chance to complete phase III trial









